Clinical Trial Results:
Pharmacokinetics of micafungin (Mycamin ®) as antifungal prophylaxis given twice weekly intravenously compared to micafungin given daily to patients at risk for developing an invasive fungal disease.
Summary
|
|
EudraCT number |
2013-002848-93 |
Trial protocol |
NL BE |
Global end of trial date |
30 May 2016
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Oct 2020
|
First version publication date |
04 Oct 2020
|
Other versions |
|
Summary report(s) |
MATADOR paper |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
UMCN-AKF13.02
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Radboudumc
|
||
Sponsor organisation address |
Geert Grooteplein 10, Nijmegen, Netherlands,
|
||
Public contact |
Roger Brüggemann, Radboud University Medical Centre, +31 243616405, roger.bruggemann@radboudumc.nl
|
||
Scientific contact |
Roger Brüggemann, Radboud University Medical Centre, +31 243616405, roger.bruggemann@radboudumc.nl
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
21 Dec 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
30 May 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 May 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
• To determine the pharmacokinetics of micafungin 300 mg given twice weekly on Mondays and Thursdays in patients at risk for developing an invasive fungal disease (patients who are being treated for acute or chronic graft versus host disease; patients receiving reduced intensity conditioning for SCT; receiving first remission induction chemotherapy for AML/MDS) compared to the pharmacokinetics of micafungin 100 mg given daily to the same population.
|
||
Protection of trial subjects |
The risk-classification is assessed as negligible to the patient population receiving study drug at the current regimens. The drug is licensed for the use investigated in this protocol. Safety data on the use of higher dose are published and very-well defined. There is no attributable risk for the application of the study protocol to the haematology patients at risk for fungal infections.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
02 Dec 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Netherlands: 9
|
||
Country: Number of subjects enrolled |
Belgium: 11
|
||
Worldwide total number of subjects |
20
|
||
EEA total number of subjects |
20
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
18
|
||
From 65 to 84 years |
2
|
||
85 years and over |
0
|
|
|||||||||||
Recruitment
|
|||||||||||
Recruitment details |
recruitment in IC. | ||||||||||
Pre-assignment
|
|||||||||||
Screening details |
The included patientswere receiving immunosuppressive therapy for acute graft-versus-host disease (aGVHD) grade II–IV, undergoing reducedintensity conditioning regimens for allogeneic HSCT, or receiving first remission-induction chemotherapy for AML/myelodysplastic syndrome (MDS), who were at least 18years of age, if female were not pregnant. | ||||||||||
Pre-assignment period milestones
|
|||||||||||
Number of subjects started |
20 | ||||||||||
Number of subjects completed |
20 | ||||||||||
Period 1
|
|||||||||||
Period 1 title |
screening
|
||||||||||
Is this the baseline period? |
Yes | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Blinding implementation details |
not applicable
|
||||||||||
Arms
|
|||||||||||
Arm title
|
screening | ||||||||||
Arm description |
screening | ||||||||||
Arm type |
no intervention | ||||||||||
Investigational medicinal product name |
micafungin screening
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Solution for solution for infusion
|
||||||||||
Routes of administration |
Intravenous use
|
||||||||||
Dosage and administration details |
in the screening period no micafungin was given
|
||||||||||
|
|||||||||||
Period 2
|
|||||||||||
Period 2 title |
900 mg mica
|
||||||||||
Is this the baseline period? |
No | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Blinding implementation details |
not applicable
|
||||||||||
Arms
|
|||||||||||
Arm title
|
mica 900mg | ||||||||||
Arm description |
- | ||||||||||
Arm type |
Experimental | ||||||||||
Investigational medicinal product name |
micafungin 900mg
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Solution for solution for infusion
|
||||||||||
Routes of administration |
Intravenous use
|
||||||||||
Dosage and administration details |
300mg of micafungin twice weekly for 8 days (Group A, receiving 900mg in total
|
||||||||||
|
|||||||||||
Period 3
|
|||||||||||
Period 3 title |
mica 800mg
|
||||||||||
Is this the baseline period? |
No | ||||||||||
Allocation method |
Randomised - controlled
|
||||||||||
Blinding used |
Not blinded | ||||||||||
Blinding implementation details |
not applicable
|
||||||||||
Arms
|
|||||||||||
Arm title
|
mica 800mg | ||||||||||
Arm description |
- | ||||||||||
Arm type |
Active comparator | ||||||||||
Investigational medicinal product name |
micafungin 800mg
|
||||||||||
Investigational medicinal product code |
|||||||||||
Other name |
|||||||||||
Pharmaceutical forms |
Solution for solution for infusion
|
||||||||||
Routes of administration |
Intravenous use
|
||||||||||
Dosage and administration details |
100mg of micafungin once daily for 8 days
|
||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
screening
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
screening
|
||
Reporting group description |
screening | ||
Reporting group title |
mica 900mg
|
||
Reporting group description |
- | ||
Reporting group title |
mica 800mg
|
||
Reporting group description |
- |
|
|||||||||||||
End point title |
area under the curve [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
0-168 hours
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: no statistical test was done to compare, only descriptive |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
entire study
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
none | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
entire group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: none reported |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/30137340 |